1
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                    FORM 8-K


                 CURRENT REPORT PURSUANT TO SECTION 13 OR 14(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


DATE OF REPORT: September 7, 2001

EXACT NAME OF REGISTRANT: AMARILLO BIOSCIENCES, INC. (the "Company")

STATE OR OTHER JURISDICTION OF INCORPORATION: Texas

COMMISSION FILE NUMBER: 0-20791

IRS EMPLOYER IDENTIFICATION NUMBER: 75-1974352

ADDRESS OF PRINCIPAL EXECUTIVE OFFICES: 800 W. 9th, Amarillo, Texas 79101

REGISTRANT'S TELEPHONE NUMBER: 806/376-1741

ITEM 5:

         On September 7, 2001, the Company entered into a License Agreement with
Atrix Laboratories, Inc. ("Atrix"). Under the Agreement, the Company licensed to
Atrix rights in the U.S., Canada, and Western and Eastern Europe to orally
administered low dose interferon alpha (IFN(alpha)) for use in the treatment of
oral papillomavirus warts in HIV-positive patients, and Behcet's disease. The
U.S. Food and Drug Administration has granted orphan drug status for both
indications to the Company. The orphan designation is designed to promote the
development of treatments for rare diseases or conditions and provides certain
marketing exclusivity incentives outlined under the Orphan Drug Act.

         Under the terms of the Agreement, Atrix paid $485,000.00 for the
exclusive rights to the two indications, within the aforesaid territory, and
will fund or perform associated research and development activities. The
Agreement provides for additional payments to the Company for specific clinical
and regulatory milestones, and for a royalty based on sales of any products that
may be developed.



   2


ITEM 7:

                                  Exhibit Index

10.44(a)   License Agreement between Atrix Laboratories, Inc. and the Company
           dated September 7, 2001


(a) Portions of this exhibit have been omitted and filed separately with the
commission pursuant to a request for confidential treatment.

                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

         Date: September 24, 2001.

                                       AMARILLO BIOSCIENCES, INC.


                                       By: /s/ EDWARD L. MORRIS
                                           -------------------------------------
                                           Edward L. Morris, Secretary



                                  Exhibit Index

10.44(a)   License Agreement between Atrix Laboratories, Inc. and the Company
           dated September 7, 2001


(a) Portions of this exhibit have been omitted and filed separately with the
commission pursuant to a request for confidential treatment.